Phase 3 Liver Cancer Trial, Recruiting NCT06041477 Sponsor: Sun Yat-sen University Condition: Liver Cancer
Back to Liver Cancer

Phase 3 Liver Cancer Trial, Recruiting

NCT06041477
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old
  • People with a general health status rated as fully active or restricted only in physically strenuous activity (confirm with trial site)
  • People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) at a specific mid-to-advanced stage, based on a Chinese liver cancer staging system (confirm with trial site)
  • People who have not yet received any treatment for their liver cancer
  • People whose cancer cannot currently be removed by surgery, but where a medical team has assessed that surgery may become possible after an initial round of treatment — for example, where multiple tumours are in one lobe of the liver, or where a blood vessel near the liver is affected but could potentially be treated along with the main tumour
  • People whose blood and organ function test results meet certain minimum levels (or could meet them with a short course of treatment), covering white blood cells, red blood cells, platelets, liver function, kidney function, and blood clotting (confirm specific values with trial site)
  • People who have been fully informed about the study and have signed a consent form

Who may not be able to join:

  • People with serious heart, brain, lung, kidney, or other major organ problems, severe infections, or other serious health conditions that would make the treatment too risky
  • People who have had another type of cancer at any point
  • People with a known history of allergic reactions to the drugs used in this trial
  • People with a known allergy to any ingredient in the targeted therapy or immunotherapy drugs used in this trial
  • People who have had an organ transplant
  • People who have previously received any treatment for liver cancer, including interferon
  • People who are HIV-positive
  • People with a history of drug abuse
  • People who have had a gastrointestinal bleed or a cardiovascular event (such as a heart attack or stroke) within the past 30 days
  • Women who are pregnant or breastfeeding, or women of childbearing age who do not wish to use contraception during the trial
  • People with a psychiatric condition that would prevent them from giving informed consent or from participating in treatment
  • Other factors that may affect a person's participation or the reliability of results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wei Wei, Ph.D, M,D, Sun Yat-sen University

Phone: 008615088064187

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
31 October 2023
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

OS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov